Sustainability at Biocon

Biocon | Acquisition of Viatris' biosimilars business to add financial depth and global commercial capabilities... 1 Financial 2 Operational BBL to realize full revenue and profits from all its collaboration programs Revenue EBITDA $1.1b | $250m Viatris Biosimilars CY23 estimate¹ Commercialization, Supply Chain and Regulatory capabilities in Developed Markets 3 New Growth Drivers Launch of collaboration products in the US Option for new in-licensed biosimilar asset bBevacizumab bAspart bAdalimumab bAflibercept Viatris to provide commercial and transition services for an expected two-year period, at cost plus $44m p.a. Note: Transaction subject to regulatory approvals | 1 BBL estimates of Viatris' business 16

View entire presentation